One Biosciences combines the power of A.I. and single-cell technologies to discover new therapeutic targets and develop novel precision medicines

Mission and Model

One Biosciences’ discovery engine includes three differentiating components :

  • 1. Protocols and know how to generate high quality single-cell and single-nuclei RNAseq datasets for in depth analyses from various human tissues, including small frozen biopsies from solid tissues
  • 2. A proprietary application ('OneApp') for the visualization, the analysis and support to interpret scRNAseq data. The agility and ease of use of this app allows for multi-disciplinary teams encompassing biologists without any computational skills to explore and interpret massive and complex scRNA seq data
  • 3. A proprietary database and architecture that is fully GDPR compliant and enables to operate with required authentication processes and secured access rights to store and process large data sets.


One Biosciences’ team, from left to right:

Hugo Cornu (Data Lead), Céline Vallot (Team Leader Institut Curie – Scientific founder One Biosciences), Marianne Delville (Project Manager), Magali Richard (CEO), David Schilansky (Chairman, representing Home Biosciences), Yuna Landais (Data Scientist), Paul Cadorin (Data Engineer), Baptiste Simon (Data Engineer).

Magali Richard

Magali has fifteen years of experience in the field of biotechnology, combining academia and industry. Magali graduated from Ecole Polytechnique and Ecole Nationale Supérieure des Mines de Paris, and holds a PhD in Molecular Biology (Paris 6).

From 2009 to 2011 she worked as a Scientist at Biomarin Pharmaceuticals, pursuing in the rare diseases space and gaining biotech experience in the United States.

Subsequently, Magali worked for 6 years at the Boston Consulting Group, working with various large pharmaceutical companies on all activities along the value chain. She then joined the Executive Committee of DBV Technologies as Chief Strategy Officer. She is today deputy CEO (Directeur Général) of Home Biosciences.

David Schilansky

David has more than twenty years of professional experience, mainly in the pharmaceutical and biotechnology industry. From 2011 to 2020, he co-headed DBV Technologies.

During this period, he led two IPOs on Euronext and Nasdaq, raising more than one billion US dollars in total. David began his career as an investment banker in M&A at Warburg, before joining Technicolor as head of financial communication.

He then worked at Ipsen, from 2005 to 2011, where he held various roles in finance, including that of Group CFO, before moving to DBV. David has been a board member of Lysogene SA, a phase III gene therapy company in CNS, since 2016. David graduated from Paris Dauphine and Imperial College (London). He is today CEO (Président) of Home Biosciences.

Céline Vallot

Céline Vallot is the head of the Dynamics of Epigenetic Plasticity group at Institut Curie (UMR3244/Translational Department). She joined the Translational Department of IC as a junior group leader in 2017 and is an expert in multi-omics data analysis and epigenetic regulation.

She got awarded an ATIP-Avenir grant in 2017, the Bronze Medal of the CNRS in 2018, and the Prix Olga Sain in 2019.

Her lab investigates the dynamics of acquisition of chromatin features in cancer cells in vivo and in vitro combining cancer biology to single-cell microfluidics and data mining. Her group has recently co-developed means to analyze the epigenome of cancer cells at single-cell resolution and revealed the heterogeneity of chromatin states within breast tumors. With her group, she has created a series of tools for single-cell data analysis. She has co-founded the single-cell facility of the IC. Céline also holds a MS from Ecole Polytechnique, Paris.

Institutional founders

Home Biosciences

Europe’s first biotech Venture Builder

Institut Curie

A leading player in the fight against cancer

Home Biosciences, President
represented by David Schilansky


Magali Richard, CEO and co-founder


Isabelle Pelletier Bressac, independent Board member


Céline Vallot, Permanent Guest
Co-founder of One Biosciences


Institut Curie, Board observer
represented by Jérémie Weber

Alexandre Gramfort, PhD
Research Director at INRIA and Professor at Polytechnique (Paris)

  • Engineer (Polytechnique -Telecom) and PhD in signal and imaging processing
  • ERC grant in 2016
  • Leading expert in machine learning and one of the architects of the scikit-learn software widely used by data scientists worldwide


Sophie Postel-Vinay, MD/PhD
Drug Development Department and U981 Research Unit at Gustave Roussy Cancer Campus

  • MD in Medical Oncology and PhD in Oncology
  • ATIP-Avenir ‘Young Group Leader’ (2017, Soeurs Lucie et Olga Fradiss award, Irene Joliot Curie award (2017)
  • Expert in chromatin remodeling, DNA repair defect, immune system modulation in solid tumor
  • Expert in early clinical trials in Oncology


Céline Vallot, PhD, chairman of the SAB
Institut Curie – Group Leader UMR3244 – Translational Department


Julien Zuber, MD/PhD
Transplant nephrologist at Necker Hospital and Professor of Clinical Immunology at Paris Descartes University

  • MD in Nephrology and PhD in Immunology
  • Expert in immunology, transplant tolerance, biotherapies and cellular therapies in clinical transplantation of solid organs to improve outcomes.


One Biosciences is a flagship company of Institut Curie, showing its ambition to support the emergence of innovative companies. It is the first venture at the crossroads of data science and single-cell analysis, which are fields of excellence of Institut Curie. We are also delighted with the strong partnership with Home Biosciences.”

Amaury Martin Deputy Director of Institut Curie, Technology Transfer, Data, Translational programs.

One Biosciences was granted a worldwide license on key technologies and necessary know-how from Institut Curie, CNRS and Sorbonne Université, in addition to a worldwide exclusive license on dedicated single-cell computational softwares, in order to generate unique insights with cutting edge single-cell approaches. The same parties have also entered into a research collaboration to expand the technical possibilities of single-cell analysis, and thus strengthen the respective leadership positions of Institut Curie’s single-cell platform and One Biosciences.